Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-28T02:31:06.715Z Has data issue: false hasContentIssue false
  • English
  • Français

Complete response in a melanoma patient treated with imatinib

Published online by Cambridge University Press:  19 April 2012

M C Brown  and
R J Casasola
M C Brown
Affiliation:
Medical School, University of Dundee, Dundee, Scotland, UK
R J Casasola*
Affiliation:
Oncology Department, Ninewells Hospital, Dundee, Scotland, UK
*
Address for correspondence: Dr Richard J Casasola, Oncology Department, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, UK E-mail: rcasasola@nhs.net
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Imatinib therapy has been successful in gastrointestinal stromal tumours containing mutation of the KIT gene. However, there are few reported cases of successful imatinib therapy in patients with melanoma containing KIT gene mutation or c-kit protein expression.

Methods and results:

A 52-year-old man developed metastatic melanoma from a primary melanoma in the left side of the nasopharynx. The tumour was positive for c-kit protein, and there was a KIT mutation in exon 11. He was treated with imatinib. A follow-up scan one year later showed a complete response. Treatment targeting the biological characteristics of melanoma proved successful in this patient.

Keywords

MelanomaProto-OncogenesC-kit ProteinNasopharynxAntineoplastic Agents
Type
Clinical Records
Information
The Journal of Laryngology & Otology , Volume 126 , Issue 6 , June 2012 , pp. 638 - 640
Copyright
Copyright © JLO (1984) Limited 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Chang, AE, Karnell, LH, Menck, HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma. Cancer 1998;83:1664–783.0.CO;2-G>CrossRefGoogle ScholarPubMed
2Cancer Research UK. Skin cancer – UK incidence statistics. In: http://info.cancerresearchuk.org/cancerstats/types/skin/incidence [29 November 2010]Google Scholar
3Manola, J, Atkins, M, Ibrahim, J, Kirkwood, J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000;18:3782–93CrossRefGoogle ScholarPubMed
4Rivera, RS, Nagatsuka, H, Gunduz, M, Cengiz, B, Gunduz, E, Siar, CH et al. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 2008;452:27–32CrossRefGoogle ScholarPubMed
5Ugurel, S, Hildenbrand, R, Zimpfer, A, La Rosée, P, Paschka, P, Sucker, A et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005;92:1398–405CrossRefGoogle ScholarPubMed
6Wyman, K, Atkins, MB, Prieto, V, Eton, O, McDermott, DF, Hubbard, F et al. Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006;106:2005–11CrossRefGoogle ScholarPubMed
7Kim, KB, Eton, O, Davis, DW, Frazier, ML, McConkey, DJ, Diwan, AH et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008;99:734–40CrossRefGoogle ScholarPubMed
8Buchdunger, E, Cioffi, CL, Law, N, Stover, D, Ohno-Jones, S, Druker, BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139–45Google ScholarPubMed
9Demetri, GD, von Mehren, M, Blanke, CD, Van den Abbeele, AD, Eisenberg, B, Roberts, PJ et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–80CrossRefGoogle ScholarPubMed
10van Oosterom, AT, Judson, I, Verweij, J, Stroobants, S, Donato, diPaola, E, Dimitrijevic, S et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421–3CrossRefGoogle ScholarPubMed
11Verweij, J, Casali, PG, Zalcberg, J, LeCesne, A, Reichardt, P, Blay, JY et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127–34CrossRefGoogle ScholarPubMed
12Rubin, BP, Heinrich, MC, Corless, CL. Gastrointestinal stromal tumour. Lancet 2007;369:1731–41CrossRefGoogle ScholarPubMed
13Torres-Cabala, CA, Wang, WL, Trent, J, Yang, D, Chen, S, Galbincea, J et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 2009;22:1446–56CrossRefGoogle ScholarPubMed
14Curtin, JA, Busam, K, Pinkel, D, Bastian, BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340–6CrossRefGoogle ScholarPubMed
15Beadling, C, Jacobson-Dunlop, E, Hodi, FS, Le, C, Warrick, A, Patterson, J et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14:6821–8CrossRefGoogle ScholarPubMed
16Jiang, X, Zhou, J, Yuen, NK, Corless, CL, Heinrich, MC, Fletcher, JA et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008;14:7726–32CrossRefGoogle ScholarPubMed
17Medeiros, F, Corless, CL, Duensing, A, Hornick, JL, Oliveira, AM, Heinrich, MC et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004;28:889–94CrossRefGoogle ScholarPubMed